Transforming into a high single digit growth company from FY 2022 onwards
Key Messages Capital Markets Day
From Mid to
High single digit
sales growth
FY 2020e: guidance confirmed
FY 2021e: mid single digit (3-7%)
From FY 2022e onward: high single digit (6-9%)
Growth push through
High Value
Solutions
For both segments pharma and cosmetics
Biologics vials and syringes
ELITE® Glass
Ready-to-fill products (RTF)
Decorated glass and PCR glass
Strong growth drivers, starting in 2021:
Gx Biologic Solutions
EBITDA margin:
steady increase with
good trajectory
Investments into
Business Opportunities
Base Capex | 4% | ||
Growth Capex | 5% | ||
Unique | |||
Business | ~3% | ||
Opportunities |
- ELITE® Glass CAGR >30%; RTF Vials CAGR >50%
- More than double sales with high value solutions
- Triple sales in biologics by 2028
FY 2020e: 22% without GAT
FY 2021e: 22-23% | Mid-term: comfortable 23%
- Product mix: ramp-up for high value solutions
- Excellence and efficiency initiatives
- Economies of scale
Disciplined value generative oriented capital allocation: ROCE target 15% - every single project will contribute
Seizing unique business opportunities by capacity expansion in injectables: IRR ~25%
Capex is not Capex - significant portion into low risk investments with excellent upside potential: contract manufacturing new auto injector contract (> IRR 25%)
GAT
(incl. Sensile)
Gerresheimer's innovation hub
Call option - Break Even expected for 2023
- Conservative approach: excl. GAT from Guidance
- Continuously good trajectory in projects, break even in FY 2023 expected
- SQ Innovation on track with good progress, first significant sales in 2022
12/9/2020 CMD Fact Sheet
Attachments
- Original document
- Permalink
Disclaimer
Gerresheimer AG published this content on 10 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 December 2020 09:48:06 UTC